{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T02:29:00Z","timestamp":1770431340253,"version":"3.49.0"},"reference-count":44,"publisher":"Oxford University Press (OUP)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[1999,6]]},"DOI":"10.1093\/jac\/43.6.747","type":"journal-article","created":{"date-parts":[[2002,7,26]],"date-time":"2002-07-26T22:24:55Z","timestamp":1027722295000},"page":"747-752","source":"Crossref","is-referenced-by-count":44,"title":["The treatment of Legionnaires\u2019 disease"],"prefix":"10.1093","volume":"43","author":[{"given":"Martin","family":"Dedicoat","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pradhib","family":"Venkatesan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[1999,6]]},"reference":[{"key":"key\n\t\t\t\t20170411034726_R1","doi-asserted-by":"crossref","unstructured":"Fraser, D. W., Tsai, T. R., Orenstein, W., Parkin, W. E., Beecham, H. J., Sharrar, R. G. et al. (1977). Legionnaires\u2019 disease: description of an epidemic of pneumonia. New England Journal of Medicine297 , 1189\u2013 97.","DOI":"10.1056\/NEJM197712012972201"},{"key":"key\n\t\t\t\t20170411034726_R2","doi-asserted-by":"crossref","unstructured":"Higa, F., Kusano, N., Tateyama, M., Shinzato, T., Araki, N., Kawakami, K. et al. (1998). Simplified quantitative assay system for measuring activities of drugs against intracellular Legionella pneumophila.Journal of Clinical Microbiology36 ,1392\u2013 8.","DOI":"10.1128\/JCM.36.5.1392-1398.1998"},{"key":"key\n\t\t\t\t20170411034726_R3","doi-asserted-by":"crossref","unstructured":"Edelstein, P. H. (1995). Antimicrobial chemotherapy for Legionnaires\u2019 disease: a review. Clinical Infectious Diseases21 , Suppl. 3 , S265\u2013 76.","DOI":"10.1093\/clind\/21.Supplement_3.S265"},{"key":"key\n\t\t\t\t20170411034726_R4","unstructured":"Joseph, C. A., Harrison, T. G., Ilijic-Car, D. & Bartlett, C. L. R. (1997). Legionnaires\u2019 disease in residents of England and Wales: 1996. Communicable Disease Report\u2014 CDR Review7 , R153\u2013 9."},{"key":"key\n\t\t\t\t20170411034726_R5","doi-asserted-by":"crossref","unstructured":"Johnson, D. M., Erwin, M. E., Barrett, M. S., Gooding, B. B. & Jones, R. N. (1992). Antimicrobial activity of ten macrolide, lincosamine and streptogramin drugs tested against Legionella species. European Journal of Clinical Microbiology and Infectious Diseases11 , 751\u2013 5.","DOI":"10.1007\/BF01989985"},{"key":"key\n\t\t\t\t20170411034726_R6","doi-asserted-by":"crossref","unstructured":"Nimmo, G. R. & Bull, J. Z. (1995). Comparative susceptibility of Legionella pneumophila and Legionella longbeachae to 12 antimicrobial agents. Journal of Antimicrobial Chemotherapy 36 , 219\u2013 23.","DOI":"10.1093\/jac\/36.1.219"},{"key":"key\n\t\t\t\t20170411034726_R7","doi-asserted-by":"crossref","unstructured":"Stout, J. E., Arnold, B. & Yu, V. L. (1998). Activity of azithromycin, clarithromycin, roxithromycin, dirithromycin, quinupristin\/dalfopristin and erythromycin against Legionella species by intracellular susceptibility testing in HL-60 cells. Journal of Antimicrobial Chemotherapy41 , 289\u2013 91.","DOI":"10.1093\/jac\/41.2.289"},{"key":"key\n\t\t\t\t20170411034726_R8","doi-asserted-by":"crossref","unstructured":"Edelstein, P. H. & Edelstein, M. A. C. (1991). In vitro activity of azithromycin against clinical isolates of Legionella species. Antimicrobial Agents and Chemotherapy35 , 180\u2013 1.","DOI":"10.1128\/AAC.35.1.180"},{"key":"key\n\t\t\t\t20170411034726_R9","doi-asserted-by":"crossref","unstructured":"Stamler, D. A., Edelstein, M. A. C. & Edelstein, P. H. (1994). Azithromycin pharmacokinetics and intracellular concentrations in Legionella pneumophila infected and uninfected guinea pigs and their alveolar macrophages. Antimicrobial Agents and Chemotherapy38 , 217\u2013 22.","DOI":"10.1128\/AAC.38.2.217"},{"key":"key\n\t\t\t\t20170411034726_R10","doi-asserted-by":"crossref","unstructured":"Fitzgeorge, R. B., Lever, S. & Baskerville, A. (1993). A comparison of the efficacy of azithromycin and clarithromycin in oral therapy of experimental airborne legionnaires\u2019 disease. Journal of Antimicrobial Chemotherapy31 , Suppl. E , 171\u2013 6.","DOI":"10.1093\/jac\/31.suppl_E.171"},{"key":"key\n\t\t\t\t20170411034726_R11","doi-asserted-by":"crossref","unstructured":"Edelstein, P. H. (1993). Legionnaires\u2019 disease. Clinical Infectious Diseases 16 , 741\u2013 9.","DOI":"10.1093\/clind\/16.6.741"},{"key":"key\n\t\t\t\t20170411034726_R12","doi-asserted-by":"crossref","unstructured":"Dorrell, L., Fulton, B. & Ong, E. L. C. (1994). Intravenous azithromycin as salvage therapy in a patient with Legionnaires\u2019 disease. Thorax49 , 620\u2013 1.","DOI":"10.1136\/thx.49.6.620"},{"key":"key\n\t\t\t\t20170411034726_R13","doi-asserted-by":"crossref","unstructured":"Kuzman, I., Soldo, I., Schonwald, S. & Culig, J. (1995). Azithromycin for treatment of community acquired pneumonia caused by Legionella pneumophila : a retrospective study. Scandinavian Journal of Infectious Diseases27 , 503\u2013 5.","DOI":"10.3109\/00365549509047054"},{"key":"key\n\t\t\t\t20170411034726_R14","doi-asserted-by":"crossref","unstructured":"Onody, C., Matsiota-Bernard, P. & Nauciel, C. (1997). Lack of resistance to erythromycin, rifampicin and ciprofloxacin in 98 clinical isolates of Legionella pneumophila.Journal of Antimicrobial Chemotherapy39 , 815\u2013 6.","DOI":"10.1093\/jac\/39.6.815"},{"key":"key\n\t\t\t\t20170411034726_R15","doi-asserted-by":"crossref","unstructured":"Hoogkamp-Korstanje, J. A. A. (1997). In-vitro activities of ciprofloxacin, levofloxacin, lomefloxacin, ofloxacin, pefloxacin, sparfloxacin and trovofloxacin against Gram-positive and Gram-negative pathogens from respiratory tract infections. Journal of Antimicrobial Chemotherapy40 , 427\u2013 31.","DOI":"10.1093\/jac\/40.3.427"},{"key":"key\n\t\t\t\t20170411034726_R16","doi-asserted-by":"crossref","unstructured":"Panteix, G., Harf, R., Desnottes, J. F., Gosselet, H., Leclerq, M., Daillo, N. et al. (1994). Accumulation of pefloxacin in the lower respiratory tract demonstrated by bronchoalveolar lavage. Journal of Antimicrobial Chemotherapy33 , 979\u2013 85.","DOI":"10.1093\/jac\/33.5.979"},{"key":"key\n\t\t\t\t20170411034726_R17","doi-asserted-by":"crossref","unstructured":"Edelstein, P. H., Edelstein, M. A. C., Ren, J., Polzer, R. & Gladue, R. P. (1996). Activity of trovofloxacin (CP-99,219) against Legionella isolates: in vitro activity, intracellular accumulation and killing in macrophages, and pharmacokinetics and treatment of guinea pigs with L. pneumophila pneumonia. Antimicrobial Agents and Chemotherapy40 , 314\u2013 19.","DOI":"10.1128\/AAC.40.2.314"},{"key":"key\n\t\t\t\t20170411034726_R18","doi-asserted-by":"crossref","unstructured":"Edelstein, P. H., Edelstein, M. A. C., Weidenfeld, J. & Dorr, M. B. (1990). In vitro activity of sparfloxacin (CI-978; AT-4140) for clinical Legionella isolates, pharmocokinetics in guinea pigs, and use to treat guinea pigs with L. pneumophila pneumonia. Antimicrobial Agents and Chemotherapy34 , 2122\u2013 7.","DOI":"10.1128\/AAC.34.11.2122"},{"key":"key\n\t\t\t\t20170411034726_R19","doi-asserted-by":"crossref","unstructured":"Edelstein, P. H., Edelstein, M. A. C., Lehr, K. H. & Ren, J. (1996). In-vitro activity of levofloxacin against clinical isolates of Legionella spp., its pharmokinetics in guinea pigs, and use in experimental Legionella pneumophila pneumonia. Journal of Antimicrobial Chemotherapy37 , 117\u2013 26.","DOI":"10.1093\/jac\/37.1.117"},{"key":"key\n\t\t\t\t20170411034726_R20","doi-asserted-by":"crossref","unstructured":"Stout, J. E., Arnold, B. & Yu, V. L. (1998). Comparative activity of ciprofloxacin, ofloxacin, levofloxacin, and erythromycin against Legionella species by broth microdilution and intracellular susceptibility testing in HL-60 cells. Diagnostic Microbiology and Infectious Disease 30 , 37\u2013 43.","DOI":"10.1016\/S0732-8893(97)00174-0"},{"key":"key\n\t\t\t\t20170411034726_R21","doi-asserted-by":"crossref","unstructured":"Topkis, S., Swarz, H., Breisch, S. A. & Maroli, A. N. (1997). Efficacy and safety of grepafloxacin 600 mg daily for 10 days in patients with community acquired pneumonia. Clinical Therapeutics19 , 975\u2013 88.","DOI":"10.1016\/S0149-2918(97)80050-1"},{"key":"key\n\t\t\t\t20170411034726_R22","doi-asserted-by":"crossref","unstructured":"File, T. M., Segreti, J., Dunbar, L., Player, R., Kohler, R., Williams, R. R. et al. (1997). A multicenter, randomized study comparing the efficacy and safety of intravenous and\/or oral levofloxacin versus ceftriaxone and\/or cefuroxime axetil in the treatment of adults with community acquired pneumonia. Antimicrobial Agents and Chemotherapy41 ,1965\u2013 72.","DOI":"10.1128\/AAC.41.9.1965"},{"key":"key\n\t\t\t\t20170411034726_R23","unstructured":"Leroy, O., Beuscart, C., Chidiac, C., Sivery, B., Senneville, E., Vincent du Laurier, M. et al. (1989). Treatment of pneumonia caused by Legionella,Mycoplasma,Chlamydia and Rickettsia using ofloxacin. Pathologie Biologie37 ,1137\u2013 40."},{"key":"key\n\t\t\t\t20170411034726_R24","doi-asserted-by":"crossref","unstructured":"Plouffe, J. F., Herbert, M. T., File, T. M., Baird, I., Parsons, J. N., Kahn, J. B. et al. (1996). Ofloxacin versus standard therapy in treatment of community-acquired pneumonia requiring hospitalization. Pneumonia Study Group. Antimicrobial Agents and Chemotherapy40 , 1175\u2013 9.","DOI":"10.1128\/AAC.40.5.1175"},{"key":"key\n\t\t\t\t20170411034726_R25","doi-asserted-by":"crossref","unstructured":"Dournon, E., Mayaud, C., Wolff, M., Sclemmer, B., Samuel, D., Sollet, J. P. et al. (1990). Comparison of the activity of three antibiotic regimens in severe Legionnaires\u2019 disease. Journal of Antimicrobial Chemotherapy26 , Suppl. B , 129\u2013 39.","DOI":"10.1093\/jac\/26.suppl_B.129"},{"key":"key\n\t\t\t\t20170411034726_R26","doi-asserted-by":"crossref","unstructured":"Aubier, M., Lode, H., Gialdroni-Grassi, G., Huchon, G., Hosie, J., Legakis, N. et al. (1996). Sparfloxacin for the treatment of community-acquired pneumonia: a pooled data analysis of two studies. Journal of Antimicrobial Chemotherapy37 , Suppl. A , 73\u2013 82.","DOI":"10.1093\/jac\/37.suppl_A.73"},{"key":"key\n\t\t\t\t20170411034726_R27","doi-asserted-by":"crossref","unstructured":"Portier, H., May, T. & Proust, A. (1996). Comparative efficacy of sparfloxacin in comparison with amoxycillin plus ofloxacin in the treatment of community-acquired pneumonia. French Study Group. Journal of Antimicrobial Chemotherapy37 , Suppl. A , 83\u2013 91.","DOI":"10.1093\/jac\/37.suppl_A.83"},{"key":"key\n\t\t\t\t20170411034726_R28","doi-asserted-by":"crossref","unstructured":"Salord, J.-M., Matsiota-Bernard, P., Staikowsky, F., Kirstetter, M., Frottier, J. & Nauciel, C. (1993). Unsuccessful treatment of Legionella pneumophila infection with a fluoroquinolone. Clinical Infectious Diseases17 , 518\u2013 19.","DOI":"10.1093\/clinids\/17.3.518"},{"key":"key\n\t\t\t\t20170411034726_R29","doi-asserted-by":"crossref","unstructured":"Reda, C., Quaresima, T. & Pastoris, M. C. (1994). In-vitro activity of six intracellular antibiotics against Legionella pneumophila strains of human and environmental origin. Journal of Antimicrobial Chemotherapy33, 757\u2013 64.","DOI":"10.1093\/jac\/33.4.757"},{"key":"key\n\t\t\t\t20170411034726_R30","doi-asserted-by":"crossref","unstructured":"Baltch, A. L., Smith, R. P. & Ritz, W. (1995). Inhibitory and bactericidal activities of levofloxacin, ofloxacin, erythromycin, and rifampin used singly and in combination against Legionella pneumophila.Antimicrobial Agents and Chemotherapy39 , 1661\u2013 6.","DOI":"10.1128\/AAC.39.8.1661"},{"key":"key\n\t\t\t\t20170411034726_R31","unstructured":"Ridgway, G. L., Salman, H., Robbins, M. J., Dencer, C. & Felmingham, D. (1997). The in-vitro activity of grepafloxacin against Chlamydia spp., Mycoplasma spp., Ureaplasma urealyticum and Legionella spp. Journal of Antimicrobial Chemotherapy40 , Suppl. A,31\u2013 4."},{"key":"key\n\t\t\t\t20170411034726_R32","doi-asserted-by":"crossref","unstructured":"Schulin, T., Wennersten, C. B., Ferraro, M. J., Moellering, R. C. & Eliopoulos, G. M. (1998). Susceptibilities of Legionella spp. to newer antimicrobials in vitro.Antimicrobial Agents and Chemotherapy42 , 1520\u2013 3.","DOI":"10.1128\/AAC.42.6.1520"},{"key":"key\n\t\t\t\t20170411034726_R33","doi-asserted-by":"crossref","unstructured":"Nowicki, M., Paucod, J. C., Bornstein, N., Meugnier, H., Isoard, P. & Fleurette, J. (1988). Comparative efficacy of five antibiotics on experimental airborne legionellosis in guinea-pigs. Journal of Antimicrobial Chemotherapy22 , 513\u2013 9.","DOI":"10.1093\/jac\/22.4.513"},{"key":"key\n\t\t\t\t20170411034726_R34","doi-asserted-by":"crossref","unstructured":"Barker, J. E. & Farrell, I. D. (1990). The effects of single and combined antibiotics on the growth of Legionella pneumophila using time- kill studies. Journal of Antimicrobial Chemotherapy26 , 45\u2013 53.","DOI":"10.1093\/jac\/26.1.45"},{"key":"key\n\t\t\t\t20170411034726_R35","doi-asserted-by":"crossref","unstructured":"Bebear, C. & Bouanchaud, D. H. (1997). A review of the in-vitro activity of quinupristin\/dalfopristin against intracellular pathogens and mycoplasmas. Journal of Antimicrobial Chemotherapy39 , Suppl. A , 59- 62.","DOI":"10.1093\/jac\/39.suppl_1.59"},{"key":"key\n\t\t\t\t20170411034726_R36","unstructured":"Edelstein, P. H. & Edelstein, M. A. C. (1999). In vitro activity of the ketolide HMR 3647 (RU 6647) for Legionella spp., its pharmacokinetics in guinea pigs, and use of the drug to treat guinea pigs with Legionella pneumophila pneumonia. Antimicrobial Agents and Chemotherapy43 , 90\u2013 5."},{"key":"key\n\t\t\t\t20170411034726_R37","doi-asserted-by":"crossref","unstructured":"Baltch, A. L., Smith, R. P., Franke, M. A. & Michelsen, P. B. (1998). Antibacterial effects of levofloxacin, erythromycin, and rifampin in a human monocyte system against Legionella pneumophila.Antimicrobial Agents and Chemotherapy42 , 3153\u2013 6.","DOI":"10.1128\/AAC.42.12.3153"},{"key":"key\n\t\t\t\t20170411034726_R38","unstructured":"Hubbard, R. B., Mathur, R. M. & MacFarlane, J. T. (1993). Severe community acquired legionella pneumonia: treatment, complications and outcome. Quarterly Journal of Medicine86 , 327\u2013 32."},{"key":"key\n\t\t\t\t20170411034726_R39","doi-asserted-by":"crossref","unstructured":"Plouffe, J. F., File, T. M., Breiman, R. F., Hackman, B. A., Salstrom, S. J., Marston, B. J. et al. (1995). Re-evaluation of the definition of Legionnaires\u2019 disease: use of the urinary antigen assay. Community Based Pneumonia Incidence Study Group. Clinical Infectious Diseases20 , 1286\u2013 91.","DOI":"10.1093\/clinids\/20.5.1286"},{"key":"key\n\t\t\t\t20170411034726_R40","unstructured":"O\u2019 Doherty, B., Dutchman, D. A., Pettit, R. & Maroli, A. (1997). Randomized, double-blind comparative study of grepafloxacin and amoxycillin in the treatment of patients with community-acquired pneumonia. 40 , Suppl. A ,73\u2013 81."},{"key":"key\n\t\t\t\t20170411034726_R41","doi-asserted-by":"crossref","unstructured":"Zachariah, J. (1996). A randomized, comparative study to evaluate the efficacy and tolerability of a 3-day course of azithromycin versus a 10-day course of co-amoxiclav as treatment of adult patients with lower respiratory tract infections. Journal of Antimicrobial Chemotherapy37 , Suppl. C ,103\u2013 13.","DOI":"10.1093\/jac\/37.suppl_C.103"},{"key":"key\n\t\t\t\t20170411034726_R42","doi-asserted-by":"crossref","unstructured":"Wise, R. & Andrews, J. M. (1997). The activity of grepafloxacin against respiratory pathogens in the UK. Journal of Antimicrobial Chemotherapy 40 , Suppl. A , 27\u2013 30.","DOI":"10.1093\/jac\/40.suppl_1.27"},{"key":"key\n\t\t\t\t20170411034726_R43","doi-asserted-by":"crossref","unstructured":"Felmingham, D., Robbins, M. J., Ingley, K., Mathias, I., Bhogal, H., Leakey, A. et al. (1997). In-vitro activity of trovafloxacin, a new fluoroquinolone, against recent clinical isolates. Journal of Antimicrobial Chemotherapy39 , Suppl. B , 43\u2013 9.","DOI":"10.1093\/jac\/39.suppl_2.43"},{"key":"key\n\t\t\t\t20170411034726_R44","doi-asserted-by":"crossref","unstructured":"Marco, F., Biedenbach, D. J. & Jones, R. N. (1997). Anti-Legionella activity of trovafloxacin compared with seven other antimicrobial agents including an intermethod evaluation. Diagnostic Microbiology and Infectious Disease29 , 55\u2013 7.","DOI":"10.1016\/S0732-8893(97)00067-9"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/43\/6\/747\/13056662\/JAC436747.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,4]],"date-time":"2020-03-04T08:23:39Z","timestamp":1583310219000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article-lookup\/doi\/10.1093\/jac\/43.6.747"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,6]]},"references-count":44,"journal-issue":{"issue":"6","published-online":{"date-parts":[[1999,6]]},"published-print":{"date-parts":[[1999,6]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/43.6.747","relation":{},"ISSN":["1460-2091","0305-7453"],"issn-type":[{"value":"1460-2091","type":"electronic"},{"value":"0305-7453","type":"print"}],"subject":[],"published":{"date-parts":[[1999,6]]}}}